Clinical and immunological features of opsoclonus-myoclonus syndrome in the era of neuronal cell surface antibodies

JAMA Neurology

Volumn 73, Issue 4, 2016, Pages 417-424

  Armangué, Thaís ^a   Sabater, Lidia ^a   Torres Vega, Estefanía ^b   Martínez Hernández, Eugenia ^a   Ariño, Helena ^a   Petit Pedrol, Mar ^a   Planagumà, Jesús ^a   Bataller, Luis ^b   Dalmau, Josep ^a,c,d   Graus, Francesc ^a,e  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; AUTOANTIBODY; EPITOPE; GLYCINE RECEPTOR ANTIBODY; MEMBRANE ANTIGEN; NEURONAL CELL SURFACE ANTIBODY; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; BRAIN DISEASE; BREAST CANCER; CELL ASSAY; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MEDICAL RECORD REVIEW; NERVE CELL CULTURE; OPSOCLONUS MYOCLONUS SYNDROME; OVARY TERATOMA; PRIORITY JOURNAL; RANKIN SCALE; RELAPSE; RETROSPECTIVE STUDY; BLOOD; CEREBROSPINAL FLUID; IMMUNOLOGY; METABOLISM; MIDDLE AGED; NERVE CELL;

ADULT; ANTIGENS, SURFACE; AUTOANTIBODIES; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEURONS; OPSOCLONUS-MYOCLONUS SYNDROME; RETROSPECTIVE STUDIES;

EID: 84963857313     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2015.4607     Document Type: Article

References (50)

1. Caviness JN, Forsyth PA, Layton DD, McPhee TJ. The movement disorder of adult opsoclonus. Mov Disord. 1995;10(1):22-27.
2. Bataller L, Graus F, Saiz A, Vilchez JJ; Spanish Opsoclonus-Myoclonus Study Group. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain. 2001;124(pt 2):437-443.
3. Klaas JP, Ahlskog JE, Pittock SJ, et al. Adult-onset opsoclonus-myoclonus syndrome. Arch Neurol. 2012;69(12):1598-1607.
4. Pike M. Opsoclonus-myoclonus syndrome. Handb Clin Neurol. 2013;112:1209-1211.
5. Pranzatelli MR. The immunopharmacology of the opsoclonus-myoclonus syndrome. Clin Neuropharmacol. 1996;19(1):1-47.
6. Ridley A, Kennard C, Scholtz CL, Büttner-Ennever JA, Summers B, Turnbull A. Omnipause neurons in two cases of opsoclonus associated with oat cell carcinoma of the lung. Brain. 1987;110(pt 6):1699-1709.
7. Young CA, MacKenzie JM, Chadwick DW, Williams IR. Opsoclonus-myoclonus syndrome: an autopsy study of three cases. Eur J Med. 1993;2(4):239-241.
8. Bataller L, Rosenfeld MR, Graus F, Vilchez JJ, Cheung NK, Dalmau J. Autoantigen diversity in the opsoclonus-myoclonus syndrome. Ann Neurol. 2003;53(3):347-353.
9. Luque FA, Furneaux HM, Ferziger R, et al. Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol. 1991;29(3):241-251.
10. Leypoldt F, Armangue T, Dalmau J. Autoimmune encephalopathies. Ann N Y Acad Sci. 2015;1338:94-114.
11. Panzer JA, Anand R, Dalmau J, Lynch DR. Antibodies to dendritic neuronal surface antigens in opsoclonus myoclonus ataxia syndrome. J Neuroimmunol. 2015;286:86-92.
12. Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75(8):1135-1140.
13. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10(1):63-74.
14. Lancaster E, Lai M, Peng X, et al. Antibodies to the GABA (B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol. 2010;9(1):67-76.
15. Van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, Van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients Stroke. 1988;19(5):604-607.
16. De Felipe-Mimbrera A, Masjuan J, Corral Í, Villar LM, Graus F, García-Barragán N. Opsoclonus-myoclonus syndrome and limbic encephalitis associated with GABAB receptor antibodies in CSF. J Neuroimmunol. 2014;272(1-2):91-93.
17. Petit-Pedrol M, Armangue T, Peng X, et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol. 2014;13(3):276-286.
18. Ilyas AA, Quarles RH, MacIntosh TD, et al. IgM in a human neuropathy related to paraproteinemia binds to a carbohydrate determinant in the myelin-associated glycoprotein and to a ganglioside. Proc Natl Acad Sci U S A. 1984;81(4):1225-1229.
19. McDonald JH, Dunn KW. Statistical tests for measures of colocalization in biological microscopy. J Microsc. 2013;252(3):295-302.
20. Takeuchi Y, Morise J, Morita I, Takematsu H, Oka S. Role of site-specific N-glycans expressed on GluA2 in the regulation of cell surface expression of AMPA-type glutamate receptors. PLoS One. 2015;10(8):e0135644.
21. Anderson NE, Budde-Steffen C, Rosenblum MK, et al. Opsoclonus, myoclonus, ataxia, and encephalopathy in adults with cancer: a distinct paraneoplastic syndrome. Medicine (Baltimore). 1988;67(2):100-109.
22. Digre KB. Opsoclonus in adults: report of three cases and review of the literature. Arch Neurol. 1986;43(11):1165-1175.
23. Armangue T, Titulaer MJ, Sabater L, et al. A novel treatment-responsive encephalitis with frequent opsoclonus and teratoma. Ann Neurol. 2014;75(3):435-441.
24. Matthay KK, Blaes F, Hero B, et al. Opsoclonus myoclonus syndrome in neuroblastoma: a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004. Cancer Lett. 2005;228(1-2):275-282.
25. De Grandis E, Parodi S, Conte M, et al. Long-term follow-up of neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome. Neuropediatrics. 2009;40(3):103-111.
26. Fernandes TD, Bazan R, Betting LE, Da Rocha FC. Topiramate effect in opsoclonus-myoclonus-ataxia syndrome. Arch Neurol. 2012;69(1):133.
27. Moretti R, Torre P, Antonello RM, Nasuelli D, Cazzato G. Opsoclonus-myoclonus syndrome: gabapentin as a new therapeutic proposal. Eur J Neurol. 2000;7(4):455-456.
28. Bartos A. Effective high-dose clonazepam treatment in two patients with opsoclonus and myoclonus: GABAergic hypothesis. Eur Neurol. 2006;56(4):240-242.
29. Ariño H, Höftberger R, Gresa-Arribas N, et al. Paraneoplastic neurological syndromes and glutamic acid decarboxylase antibodies. JAMA Neurol. 2015;72(8):874-881.
30. Candler PM, Dale RC, Griffin S, et al. Post-streptococcal opsoclonus-myoclonus syndrome associated with anti-neuroleukin antibodies. J Neurol Neurosurg Psychiatry. 2006;77(4):507-512.
31. Morales-Briceño H, Rodríguez-Violante M, Cervantes-Arriaga A, Irani SR, Lees AJ, Silveira-Moriyama L. Opsoclonus myoclonus syndrome associated with GQ1b antibodies. Mov Disord. 2012;27(13):1615-1616.
32. Scott KM, Parker F, Heckmann JM. Opsoclonus-myoclonus syndrome and HIV-infection. J Neurol Sci. 2009;284(1-2):192-195.
33. Smith JH, Dhamija R, Moseley BD, et al. N-methyl-D-aspartate receptor autoimmune encephalitis presenting with opsoclonusmyoclonus: treatment response to plasmapheresis. Arch Neurol. 2011;68(8):1069-1072.
34. Kurian M, Lalive PH, Dalmau JO, Horvath J. Opsoclonus-myoclonus syndrome in anti-N-methyl-D-aspartate receptor encephalitis. Arch Neurol. 2010;67(1):118-121.
35. Player B, Harmelink M, Bordini B, Weisgerber M, Girolami M, Croix M. Pediatric opsoclonus-myoclonus-ataxia syndrome associated with anti-N-methyl-D-aspartate receptor encephalitis. Pediatr Neurol. 2015;53(5):456-458.
36. Van Toorn R, Rabie H, Warwick JM. Opsoclonus-myoclonus in an HIV-infected child on antiretroviral therapy: possible immune reconstitution inflammatory syndrome. Eur J Paediatr Neurol. 2005;9(6):423-426.
37. Kanjanasut N, Phanthumchinda K, Bhidayasiri R. HIV-related opsoclonus-myoclonus-ataxia syndrome: report on two cases. Clin Neurol Neurosurg. 2010;112(7):572-574.
38. Ayarza A, Parisi V, Altclas J, et al. Opsoclonus-myoclonus-ataxia syndrome and HIV seroconversion. J Neurol. 2009;256(6):1024-1025.
39. Wiersinga WJ, Prins JM, Van De Beek D. Therapy-resistant opsoclonus-myoclonus syndrome secondary to HIV-1 infection. Clin Infect Dis. 2012;54(3):447-448.
40. Lynch JW. Native glycine receptor subtypes and their physiological roles. Neuropharmacology. 2009;56(1):303-309.
41. Horn AK, Büttner-Ennever JA, Wahle P, Reichenberger I. Neurotransmitter profile of saccadic omnipause neurons in nucleus raphe interpositus. J Neurosci. 1994;14(4):2032-2046.
42. Carvajal-González A, Leite MI, Waters P, et al. Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain. 2014;137(pt 8):2178-2192.
43. Iizuka T, Leite MI, Lang B, et al. Glycine receptor antibodies are detected in progressive encephalomyelitis with rigidity and myoclonus (PERM) but not in saccadic oscillations. J Neurol. 2012;259(8):1566-1573.
44. Martinez-Hernandez E, Sepulveda M, Rostásy K, et al. Antibodies to aquaporin 4, myelin-oligodendrocyte glycoprotein, and the glycine receptor a1 subunit in patients with isolated optic neuritis. JAMA Neurol. 2015;72(2):187-193.
45. Ariño H, Gresa-Arribas N, Blanco Y, et al. Cerebellar ataxia and glutamic acid decarboxylase antibodies: immunologic profile and long-term effect of immunotherapy. JAMA Neurol. 2014;71(8):1009-1016.
46. Gurrola-Diaz C, Lacroix J, Dihlmann S, Becker CM, Von Knebel Doeberitz M. Reduced expression of the neuron restrictive silencer factor permits transcription of glycine receptor alpha1 subunit in small-cell lung cancer cells. Oncogene. 2003;22(36):5636-5645.
47. Hozumi I, Sato S, Tunoda H, et al. Shared carbohydrate antigenic determinant between the myelin-associated glycoprotein (MAG) and lung cancers: an immunohistochemical study by an anti-MAG IgM monoclonal antibody. J Neuroimmunol. 1987;15(2):147-157.
48. Willison HJ, Minna JD, Brady RO, Quarles RH. Glycoconjugates in nervous tissue and small cell lung cancer share immunologically cross-reactive carbohydrate determinants. J Neuroimmunol. 1986;10(4):353-365.
49. Matà S, Ambrosini S, Mello T, Lolli F, Minciacchi D. Anti-myelin associated glycoprotein antibodies recognize HNK-1 epitope on CNS. J Neuroimmunol. 2011;236(1-2):99-105.
50. Kizuka Y, Oka S. Regulated expression and neural functions of human natural killer-1 (HNK-1) carbohydrate. Cell Mol Life Sci. 2012;69(24):4135-4147.